AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
- Written by PR Newswire
![]() |
TOKYO, June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune diseases, today announced it has been awarded a grant of up to $40 million from the Japan Agency for Medical...
Read more: AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program